

AWARD NUMBER: W81XWH-17-1-0667

TITLE: Neurovascular Changes Associated with Olfactory Deficits in Early Parkinson's Disease

PRINCIPAL INVESTIGATOR: Jun Hua

CONTRACTING ORGANIZATION: Kennedy Krieger Institute
Kirby Center, KKI, 707 N Broadway, Baltimore MD 21205

REPORT DATE: OCTOBER 2020

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE OCTOBER 2020		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2019 - 29 Sep 2020	
4. TITLE AND SUBTITLE Neurovascular Changes Associated with Olfactory Deficits in Early Parkinsons's Disease				5a. CONTRACT NUMBER W81XWH-17-1-0667	
				5b. GRANT NUMBER PD160104	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jun Hua E-Mail: jhua@mri.jhu.edu				5d. PROJECT NUMBER 0011033158	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) HUGO W. MOSER RESEARCH INSTITUTE AT KENN KAREN R. COX 707 N BROADWAY BALTIMORE MD 21205-1832				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this study is to investigate neurovascular changes related to the olfactory deficits in early PD patients to develop novel biomarkers for PD. We plan to focus on these Specific Aims: 1) neurovascular abnormalities associated with olfactory deficits in early PD patients; 2) dynamic changes in neurovascular and metabolic parameters during olfactory stimuli in early PD patients; and 3) the progression of such neurovascular abnormalities across different stages of PD patients. During the third year, we have been focusing our efforts on patient recruitment and data acquisition and analysis. We recruited 17 patients and 3 controls in Year 3, slightly exceeding the stated recruitment target in the SOW. We continued to analyze the neuroimaging and clinical data acquired in PD patients. We published some of our initial results in the form of a peer reviewed journal article.					
15. SUBJECT TERMS Parkinson's disease, olfaction, neurovascular, imaging, non-invasive, MRI, ultra-high field, arteriole, olfactory cortex, BOLD, functional MRI, biomarker					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	14	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	6
5. Changes/Problems.....	6
6. Products, Inventions, Patent Applications, and/or Licenses.....	7
7. Participants & Other Collaborating Organizations.....	8
8. Special Reporting Requirements.....	9
9. Appendices.....	10

1. INTRODUCTION:

A major hurdle for treatment development in Parkinson's Disease (PD) has been the lack of reliable measures to evaluate the efficacy of experimental therapeutic strategies. The investigation of functional deficits and associated physiological abnormalities in early PD may advance our understanding of the neuropathology, and facilitate the development of in vivo biomarkers for assessing disease progression and evaluating efficacy in therapeutic trials. Olfactory deficits in PD are prevalent, can precede motor symptoms, and are associated with alpha-synuclein pathology, which is a major pathological hallmark of PD. Therefore, non-invasive and repeatable in vivo measures (such as neurovascular measures) associated with olfactory deficits may be excellent candidates as quantitative in vivo biomarkers in early PD for tracking disease progression and evaluating treatment outcomes. Such measures may provide more specific and sensitive information, and may change earlier and faster with disease progression compared to behavioral measures of olfactory functions. Neurovascular abnormalities have been linked to the neuropathology and functional deficits in PD. In this study, we will use advanced MRI technologies developed at ultra-high field (7T) to investigate neurovascular changes related to the olfactory system in the brain in early PD patients. The enhanced sensitivity at 7T will allow us to detect subtle changes with unprecedented spatial specificity, and the advanced MRI methods developed by us will enable us to study physiological changes in specific types of blood vessels (arteriolar, capillary, and venous), and to detect robust fMRI signals in brain regions close to air cavities (resulting in large artifacts with conventional methods) such as the olfactory cortex. We will focus on the following Specific Aims: 1) To investigate neurovascular abnormalities associated with olfactory deficits in early PD patients; 2) To measure dynamic changes in neurovascular and metabolic parameters during olfactory stimuli in early PD patients; and 3) To conduct a cross-sectional study on the progression of such neurovascular abnormalities across different stages of PD patients.

2. KEYWORDS:

Parkinson's disease, olfaction, neurovascular, imaging, non-invasive, MRI, ultra-high field, arteriole, olfactory cortex, BOLD, functional MRI, biomarker

3. ACCOMPLISHMENTS:

What were the major goals of the project?

- a) Local IRB and HRPO approval, Month 3, completed.
- b) Participant recruitment, clinical Assessment, MRI and analysis: We plan to recruit 60 subjects in the proposed study: 25 early or Hoehn&Yahr stage 1 (Aims 1&2) and 15 stage 2-3 (Aim 3) PD patients, and 20 healthy controls. Target enrollment for Q1-Q4 Year 1: 7+6+6+6, Q1-Q4 Year 2: 7+6+6+6, Q1-Q2 Year 3: 5+5.

▪ **What was accomplished under these goals?**

In Year 3, we have been focusing our efforts on patient recruitment and data acquisition and analysis. In addition to the recruitment sources listed in our original proposal, to expedite recruitment, we have expanded the recruitment pool by reaching out to regional community providers to request sending subjects. With these efforts, we established a database of approximately 100 potential patients to screen, contact, and recruit for the study.

Table 1: Summary of recruitment.	Recruitment		Completed data acquisition	
	Patient	Control	Patient	Control
Year 3 Q1	0	3	0	3
Year 3 Q2	7	0	4	0
Year 3 Q3	10	0	0	0
Year 3 Q4	0	0	0	0
Year 3 total:	17	3	4	3
Year 2 total:	21	7	12	4
Year 1 total:	2	16	0	16
Year 1, 2, and 3 total:	40	26	16	23

As shown in **Table 1**, in Year 3, we recruited 17 patients and 3 controls (slightly exceeding the stated recruitment target in the SOW), and completed MRI and clinical data acquisition on 4 patients and 3 healthy control subjects. MRI scans for the other recruited participants have been scheduled to occur in the following quarters.

To date (Year 1, 2 and 3 combined), we have recruited 40 PD patients and 26 controls, and have completed MRI and clinical data acquisition in 16 PD patients and 23 healthy control subjects.

COVID-19: In Q3 and Q4 of Year 3, participant visits for data acquisition had to be rescheduled due to the COVID-19 restrictions from the institute. Recruitment was still on-going during this period. The study has recently been approved to restart, and we expect to resume data acquisition in the next quarter.

In Year 3, we continued to conduct data analysis. In addition to the olfactory functional MRI experiments reported last year, we also started to analyze the cerebral blood volume (CBV) and clinical (behavioral and cognitive) assessment data collected in the project. We had some preliminary findings in the data acquired and analyzed so far. In PD patients with normal cognition (n=10), CBVa was significantly decreased in the substantia nigra, caudate and putamen when compared to controls. In PD patients with impaired cognition (n=6), CBVa showed a decreasing trend in the substantia nigra, caudate and putamen, but was significantly increased in the presupplementary motor area and intracalcarine gyrus compared to controls. We published this preliminary result in the following peer reviewed paper:

Paez AG, Gu C, Rajan S, Miao X, Cao D, Kamath V, Bakker A, Unschuld PG, Pantelyat A, Rosenthal LS, Hua J. Differential changes in arteriolar cerebral blood volume between Parkinson's disease patients with normal and impaired cognition and mild cognitive impairment (MCI) patients without movement disorder – an exploratory study. Tomography. 2020 Aug, accepted. See appendix.

We will continue data analysis in the next year, and will follow up with these results when the data acquisition is completed for the entire study.

Stated Goals Not Met

The stated target recruitment in the SOW was met and slightly exceeded during this period.

- **What opportunities for training and professional development has the project provided?**

Nothing to report.

- **How were the results disseminated to communities of interest?**

Nothing to report.

- **What do you plan to do during the next reporting period to accomplish the goals?**

We will continue to focus our efforts on patient recruitment and data acquisition. We will also continue to analyze the collected data for all three aims stated in the proposal.

4. **IMPACT:**

- **What was the impact on the development of the principal discipline(s) of the project?**

Nothing to report.

- **What was the impact on other disciplines?**

Nothing to report.

- **What was the impact on technology transfer?**

Nothing to report.

- **What was the impact on society beyond science and technology?**

Nothing to report.

5. **CHANGES/PROBLEMS:**

- **Changes in approach and reasons for change**

Nothing to report.

- **Actual or anticipated problems or delays and actions or plans to resolve them**

Nothing to report.

- **Changes that had a significant impact on expenditures**

Nothing to report.

- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to report.

- **Significant changes in use or care of human subjects**

Nothing to report.

- **Significant changes in use or care of vertebrate animals.**

Nothing to report.

- **Significant changes in use of biohazards and/or select agents**

Nothing to report.

6. PRODUCTS:

- **Publications, conference papers, and presentations**

- **Journal publications.**

Paez AG, Gu C, Rajan S, Miao X, Cao D, Kamath V, Bakker A, Unschuld PG, Pantelyat A, Rosenthal LS, Hua J. Differential changes in arteriolar cerebral blood volume between Parkinson's disease patients with normal and impaired cognition and mild cognitive impairment (MCI) patients without movement disorder – an exploratory study. Tomography. 2020 Aug, accepted. See appendix.

- **Books or other non-periodical, one-time publications.**

Nothing to report.

- **Other publications, conference papers, and presentations.**

Nothing to report.

- **Website(s) or other Internet site(s)**

Nothing to report.

- **Technologies or techniques**

Nothing to report.

- **Inventions, patent applications, and/or licenses**

Nothing to report.

- **Other Products**

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

- What individuals have worked on the project?

Name:	<i>Jun Hua</i>
Project Role:	<i>PI</i>
Researcher Identifier (e.g. ORCID ID):	<i>JUNHUA</i>
Nearest person month worked:	<i>2</i>
Contribution to Project:	<i>Dr. Hua prepared the IRB protocol for this study, which was approved by the JHU IRB and the HRPO. He interviewed several candidates for the postdoc/research associate position and recruited a highly qualified person for this important position. He implemented and optimized the MRI pulse sequences on the 7T MRI system as proposed in the study. He developed and implemented robust technology to achieve ideal B0/B1 shim, which is critical for the optimization of the MRI pulse sequences needed in this study on the new 8-channel 7T MRI system. He supervised the data acquisition and analysis. He organized regular meetings to coordinate and speed up the efforts for patient recruitment.</i>
Funding Support:	<i>N/A</i>

Name:	<i>Adrian Paez</i>
Project Role:	<i>Research coordinator</i>
Researcher Identifier (e.g. ORCID ID):	<i>N/A</i>
Nearest person month worked:	<i>12</i>
Contribution to Project:	<i>Mr. Paez assisted in the preparation of the IRB protocol. He has completed all trainings needed for recruitment and cognitive evaluation. He implemented the olfactometer setup for the olfactory fMRI experiments in the study. He implemented and optimized the MRI pulse sequences needed for this study on the new 8-channel 7T system. He has been working with the clinics to screen and recruit study participants. He conducted all data acquisition and analysis.</i>
Funding Support:	<i>N/A</i>

- Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to report.

- What other organizations were involved as partners?

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

▪ COLLABORATIVE AWARDS:

Nothing to report.

▪ QUAD CHARTS:

Neurovascular Changes Associated with Olfactory Deficits in Early Parkinson's Disease

PD160104, W81XWH-17-1-0667

PI: Jun Hua Org: HUGO W. MOSER RESEARCH INSTITUTE AT KENNEDY KRIEGER Award Amount: \$531,188.00




Study/Product Aim(s)

- Aim 1: Neurovascular abnormalities associated with olfactory deficits in early PD patients.
- Aim 2: Dynamic changes in neurovascular and metabolic parameters during olfactory stimuli in early PD patients.
- Aim 3: Cross-sectional study on the progression of neurovascular abnormalities associated with olfactory deficits across different stages of PD patients.

Approach

Advanced MRI methods developed at 7T will be used to measure neurovascular changes in related brain regions in early PD patients and controls (Aim 1). We will also measure dynamic responses of neurovascular parameters during olfactory stimulation in related brain regions (Aim 2). These MRI measures will be correlated with olfactory test scores, and compared to brain atrophy in the same regions.



Activated brain regions during olfactory stimulation detected by the recently developed T2prep BOLD fMRI approach. The olfactory cortex is notoriously difficult to image with conventional fMRI methods due to larger susceptibility artifacts. With our T2prep BOLD fMRI, robust activation can be detected in regions related to olfaction.

Timeline and Cost

Activities	CY	17	18	19	20
IRB, personnel and other prep		█	█		
Aim 1			█	█	
Aim 2				█	█
Aim 3					█
Estimated Budget (\$K)		\$000	\$000	\$000	\$000

Updated: 09/29/2020

Goals/Milestones

CY17 Goal – IRB approval, personnel recruitment and other preparation

- IRB approval and personnel recruitment.

CY18 Goals – Aim 1

- Experimental setup and optimization.
- Patient recruitment, MRI and analysis.

CY19 Goal – Aim 2

- Patient recruitment, MRI and analysis.

CY20 Goal – Aim 3

- Patient recruitment, MRI and analysis.

Comments/Challenges/Issues/Concerns

- If timelines change, comment here.
- If off by more than one quarter in spending, comment here.

Budget Expenditure to Date

Projected Expenditure:

Actual Expenditure:

9. APPENDICES:

Journal publication:

Paez AG, Gu C, Rajan S, Miao X, Cao D, Kamath V, Bakker A, Unschuld PG, Pantelyat A, Rosenthal LS, Hua J. Differential changes in arteriolar cerebral blood volume between Parkinson's disease patients with normal and impaired cognition and mild cognitive impairment (MCI) patients without movement disorder – an exploratory study. *Tomography*. 2020 Aug, accepted. Proof attached next.

Differential Changes in Arteriolar Cerebral Blood Volume between Parkinson's Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorder – An Exploratory Study

Adrian G. Paez^{1,2}, Chunming Gu^{1,2,3}, Suraj Rajan^{4,5}, Xinyuan Miao^{1,2}, Di Cao^{1,2,3}, Vidyulata Kamath⁵, Arnold Bakker⁵, Paul G. Unschuld⁶, Alexander Y. Pantelyat⁴, Liana S. Rosenthal⁴, and Jun Hua^{1,2}

¹F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD; ²Neurosection, Division of MR Research, Department of Radiology, ³Department of Biomedical Engineering; ⁴Department of Neurology; and ⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; and ⁶Department of Psychogeriatric Medicine, Psychiatric University Hospital Zurich, Zurich, Switzerland

Corresponding Author:

Jun Hua, PhD
Department of Radiology, Johns Hopkins University School of Medicine,
F.M. Kirby Research Center for Functional Brain Imaging, Kennedy
Krieger Institute, 707 N Broadway, Baltimore, MD, 21205,
E-mail: jhua@mri.jhu.edu

Key Words: Dementia, blood vessel, perfusion, iVASO, MRI

Abbreviations: Parkinson's disease (PD), mild cognitive impairment (MCI), arteriolar cerebral blood volume (CBVa), PD dementia (PDD), cerebral blood flow (CBF), presupplementary motor area (preSMA), inflow-based vascular-space-occupancy (iVASO), gray matter (GM), time of repetition (TR), time of inversion (TI), statistical parametric mapping (SPM), signal-to-noise ratio (SNR), magnetic resonance imaging (MRI), Unified Parkinson's Disease Rating Scale (UPDRS)

ABSTRACT

Cognitive impairment amongst Parkinson's disease (PD) patients is highly prevalent and associated with an increased risk of dementia. There is growing evidence that altered cerebrovascular functions contribute to cognitive impairment. Few studies have compared cerebrovascular changes in PD patients with normal and impaired cognition and those with mild-cognitive-impairment (MCI) without movement disorder. Here, we investigated arteriolar-cerebral-blood-volume (CBVa), an index reflecting the homeostasis of the most actively regulated segment in the microvasculature, using advanced MRI in various brain regions in PD and MCI patients and matched controls. Our goal is to find brain regions with altered CBVa that are specific to PD with normal and impaired cognition, and MCI-without-movement-disorder, respectively. In PD patients with normal cognition (n=10), CBVa was significantly decreased in the substantia nigra, caudate and putamen when compared to controls. In PD patients with impaired cognition (n=6), CBVa showed a decreasing trend in the substantia nigra, caudate and putamen, but was significantly increased in the presupplementary motor area and intracalcarine gyrus compared to controls. In MCI-patients-without-movement-disorder (n=18), CBVa was significantly increased in the caudate, putamen, hippocampus and lingual gyrus compared to controls. These findings provide important information for efforts towards developing biomarkers for the evaluation of potential risk of PD dementia (PDD) in PD patients. The current study is limited in sample size and therefore is exploratory in nature. The data from this pilot study will serve as the basis for power analysis for subsequent studies to further investigate and validate the current findings.

INTRODUCTION

Parkinson's disease (PD) is defined by its characteristic motor symptoms of bradykinesia, rigidity, and tremors. However, non-motor symptoms such as cognitive impairment are frequently reported in PD, with more than one-third of patients showing signs of impairment in at least one cognitive domain at the time of diagnosis with PD (1). Gaining a better understanding of the mechanistic underpinnings of cognitive impairment is important, as cognitive impairment is associated with accelerated functional decline and neuropsychiatric symptoms including anxiety and

depression, and the risk of progression to dementia is over four times greater in PD patients with cognitive impairment than in PD patients with normal cognition (2, 3). Despite significant efforts, currently there is no robust measure to predict which patients with PD are at the greatest risk of developing PD dementia (PDD).

Cognitive impairment in PD is likely due to the presence of pathologic alpha-synuclein in the cortex, although in ~30% of individuals, there is additional amyloid and tau pathology (4–6). There is also growing evidence that cerebrovascular disease is an

important contributor to cognitive impairment. Cerebrovascular abnormalities including altered cerebral blood flow (CBF), cerebral blood volume (CBV), and blood–brain barrier permeability (7–10) have been linked with pathophysiology in various dementias (11, 12). Following those reports(13), we previously used advanced neuroimaging methods to show increased volumes of small pial arteries and arterioles (arteriolar cerebral blood volume, CBVa) in several brain regions such as the orbitofrontal cortex and the hippocampus in elderly adults with mild cognitive impairment (MCI) compared with the volumes of those in age-matched elderly controls. Cerebral vascular risk factors have also been associated with PDD. Within PDD, there is growing recognition regarding the importance of vascular pathology. Among individuals in the Parkinson's Progression Markers Initiative cohort, we found that the rate of change in measures of global cognition was greater among those with white matter hyperintensities on magnetic resonance imaging (MRI) (14). Altered CBF, CBV, and microvasculature have also been shown in patients with PD (15–23). However, to date, few studies have examined and compared cerebrovascular changes in PD patients with normal cognition, PD patients with impaired cognition, and MCI due to

Alzheimer disease (AD)-related cognitive impairment and AD-related cognitive impairment manifest differently (24), with the former being a subcortical dementia and the latter a cortical dementia (25–28). The type and regional distribution of pathology differ between PD and AD. The pathognomonic changes in PD include loss of pigmented dopaminergic cells and presence of Lewy bodies in the substantia nigra (29, 30). Dopamine loss changes the relationship within the basal ganglia pathways and subsequently changes the signaling between the basal ganglia and the cortex, leading to motor and some executive dysfunctions observed in individuals with PD (31). Indeed, multiple studies have shown small blood vessel damage in patients with PD, mainly in the substantia nigra, caudate, and putamen (15–23). The presupplementary motor area (preSMA) receives significant inputs from the basal ganglia and, in individuals with PD, significant atrophy (32), metabolic changes (33), and hypoactivation (34) have been observed in their preSMA. These are considered to be markers of changes in motor planning and not cognitive change per se. Although hypoactivation and atrophy in the entorhinal cortex, hippocampus, parahippocampus, and posterior cingulate gyrus have been identified in individuals with AD (26–28, 35) and in those with PD-related cognitive changes (36–38), other brain regions including the intracalcarine gyrus (39), thalamus (40), and lingual gyrus (41) appear to subserve PD-related cognitive impairment than AD-related amnesic MCI. Still other areas such as the nucleus accumbens (26–28, 42, 43) are affected primarily in AD-type dementia than in PD-related cognitive impairment. Different patterns of neuronal loss were reported in the nucleus basalis of Meynert in AD, PD, and PDD (44).

In this study, we used the inflow-based vascular-space-occupancy (iVASO) MRI approach (45–50) to determine potential arteriolar abnormalities (CBVa) in the brain in a cohort of patients with MCI without movement disorder and matched controls. Pial arteries and arterioles are the most actively regulated

blood vessels (51–55) and are affected by aging before venous vessels (56). Therefore, the measurement of changes in CBVa may provide a more sensitive marker than measurement of changes in total CBV and CBF, which include both arteriolar and venous vessels. Hua et al. (13) have previously reported on the MCI without movement disorder cohort and their data has been reanalyzed here with a different approach (see Methods). Based on the literature discussed previously, CBVa in preselected brain regions was calculated and compared in patients and matched controls in each cohort, with the goal of finding brain regions with altered CBVa that are specific to PD with normal cognition, PD with impaired cognition, and MCI without movement disorder.

METHODS

Study Participants

In total, 2 cohorts of participants were recruited for this study. The first cohort includes 10 PD patients with normal cognition, 6 PD patients with impaired cognition, and 7 healthy controls matched in age, sex, and education level. All patients with PD had a clinically established or clinically probable PD diagnosis according to the criteria described in the study by Postuma et al. (57). The Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (58, 59) was used as a key part to evaluate clinical symptoms. All participants were recruited through the Johns Hopkins Parkinson's Disease and Movement Disorders Center. This study has been approved by the Johns Hopkins Institutional Review Boards. Demographic data for this PD cohort are summarized in Table 1.

The second cohort consists of 18 MCI patients without movement disorder and 22 age-, sex-, and education-matched cognitively normal controls. This second cohort was recruited at the University of Zurich, Switzerland. The current study uses recently published MRI and clinical data of this cohort (13). The published MRI data was reanalyzed using a different method in the current study (see Data Analysis). As reported earlier, the study procedures were in accordance with guidelines issued by the local ethics committee (Kantonale Ethikkommission Zürich), as well as with the Declaration of Helsinki (60). Demographic data for this MCI without movement disorder cohort are summarized in Table 2 [data indicated in Table 2 has been published recently in (13)].

In both cohorts, each participant gave written informed consent for their participation. Each participant completed an MRI session on a 7T human MRI system and received a cognitive assessment (see Cognitive Assessment). None of the participants had other neurologic disorders or met *Diagnostic and Statistical Manual-5* criteria for psychiatric disorders.

Cognitive Assessment

All participants completed a cognitive assessment. All cognitive tests were administered and scored according to standardized procedures. The cognitive battery for the PD cohort consists of the following tests:

- (1) The Logical Memory Subset of the Wechsler Memory Scale (WMS–III) (62)

Table 1. Demographic Data and Clinical and Cognitive Assessment of the Parkinson’s Disease (PD) Cohorts

	Controls (Con)	PD Cognitive Normal (PDcn)	PD Cognitive Impaired (PDci)	Overall	P ^a		
					PDcn vs Con	PDci vs Con	PDci vs PDcn
Demographics							
N	7	10	6	N/A	N/A	N/A	N/A
Sex (female)	4	5	3	.95	.77	.80	1
Age (years)	59.86 ± 6.09 ^b	64.90 ± 7.85	66.33 ± 10.37	.32	.16	.22	.78
Education (years)	15.71 ± 2.69	17.20 ± 1.40	16.50 ± 3.21	.46	.22	.65	.63
Disease Duration (years)	N/A	2.80 ± 1.34	3.36 ± 1.41	N/A	N/A	N/A	.45
Unified Parkinson’s Disease Rating Scale							
Motor	N/A	25.11 ± 8.09	27.02 ± 6.33	N/A	N/A	N/A	.55
Neuropsychological Assessment							
Logical Memory Subset of the Wechsler Memory Scale	26.75 ± 6.80	27.30 ± 4.19	19.00 ± 5.57	.02	.80	.05	.02
Logical Memory Subset of the Wechsler Memory Scale Recall	25.00 ± 5.29	25.20 ± 4.47	11.60 ± 7.06	.001	.95	.01	.009
Controlled Oral Word Association Test	88.50 ± 16.20	97.30 ± 12.92	70.00 ± 15.76	.007	.108	.04	.01
HVLT-R Learning Trials	22.00 ± 6.32	23.90 ± 5.00	14.80 ± 4.32	.02	.62	.05	.005
HVLT-R Recall	6.75 ± 2.63	7.40 ± 3.66	3.60 ± 2.88	.14	.72	.13	.05
60-Item Boston Naming Test	51.67 ± 3.51	52.30 ± 1.34	53.80 ± 6.22	.06	.08	.06	.08
Longest Digit Span Forward	6.75 ± 9.00	6.70 ± 1.83	7.00 ± 2.00	.95	.95	.81	.79
Longest Digit Span Backward	5.00 ± 7.00	5.70 ± 1.34	4.60 ± 1.34	.25	.13	.54	.17

Please see Methods on details regarding the test applied.

^a P values were derived with the ANOVA, chi-square test, or t test, as appropriate.

^b mean ± standard deviation.

- (2) Controlled Oral Word Association Test (COWAT) (62)
- (3) Hopkins Verbal Learning Test–Revised (HVLT-R) (62)
- (4) The 60-item Boston Naming Test–2nd Edition (BNT-60) (62)
- (5) Digit Span Forward and Backward (63).

Individuals were classified as either PD with normal cognition or PD with impaired cognition according to the Level 1 classification outlined by Litvan et al. (64). In particular, individuals with impairment on at least 2 tests were stratified to the PD with impaired cognition group.

In the MCI without movement disorder cohort, the following cognitive tests were performed:

- (1) The Mini-Mental State Exam (MMSE)
- (2) The Revised Boston Naming Test (BNT-15) (65)
- (3) Digit Span Backward (63)
- (4) Trail Making Test (TMT) (66)
- (5) Verbal Learning and Memory Test (VLMT) (67).

Participants were categorized as cognitively normal or cognitively impaired according to established criteria (61).

MRI

Participants in both cohorts underwent a 7T MRI scan (Philips MRI scanner; Philips Healthcare, Best, The Netherlands). The hardware and software on the 7T MRI systems at both sites were identical. A 32-channel phased-array head coil (Nova Medical,

Wilmington, MA) was used for radiofrequency reception and a head-only quadrature coil for transmittal. High-resolution anatomical images were acquired with a 3D Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence (voxel = 0.75 mm isotropic) (68, 69). A 3D iVASO MRI scan covering the entire brain (13, 70, 71) was performed to measure regional gray matter (GM) CBVa using the following parameters: time of repetition (TR)/time of inversion (TI) = 10 000/1383, 5000/1093, 3800/884, 3100/714, 2500/533, and 2000/356 millisecond; voxel = 3.5 × 3.5 × 5 mm³, slices = 20; and parallel imaging acceleration (SENSE) = 2 × 2. A reference scan (TR = 20 seconds, other parameters identical) was obtained so that the scaling factor M0 in iVASO images can be determined to calculate absolute CBVa values.

Data Analysis

The statistical parametric mapping (SPM) software package (Version 8, Wellcome Trust Centre for Neuroimaging, London, United Kingdom; <http://www.fil.ion.ucl.ac.uk/spm/>) and other in-house code programmed in Matlab (MathWorks, Natick, MA) were used for image analyses. Motion correction in iVASO images, coregistration between anatomical and iVASO images, and normalization to the Montreal Neurological Institute space were performed using SPM. Regional GM CBVa maps in the whole brain were calculated from the iVASO signals after

Table 2. Demographic Data and Clinical and Cognitive Assessment of the Age-Related MCI Patients Without Movement Disorder

	Controls	Age-Related MCI Patients Without Movement Disorder	<i>P</i> ^a
Demographics			
N	22	18	N/A
Sex (female)	8	6	1
Age (year)	72 ± 5 ^b	75 ± 7	.08
Education (year)	13.64 ± 2.56	15.06 ± 3.28	.13
Number of APOE4 Alleles	7	9	N/A
Neuropsychological Assessment			
Mini-Mental State Exam	29.45 ± 0.86	28.44 ± 1.42	.01
15-Item Boston Naming Test	14.41 ± 0.73	14.17 ± 1.25	.47
Digit Span Backward	6.27 ± 1.39	5.94 ± 1.76	.52
Verbal Learning and Memory	11.05 ± 2.57	5.39 ± 2.93	<.001
Trail Making B/A	2.98 ± 1.37	2.75 ± 1.40	.62

Please see Methods on details regarding the test applied; Data indicated in Table 2 have been published recently in (13).

^a*P* values from 2-sample *t* tests between the 2 groups, or from chi-square test for categorical variables.

^bmean ± standard deviation.

surround subtraction (72) based on the iVASO equations [73]. GM, white matter, and cerebrospinal fluid maps generated from the anatomical images using the SPM segmentation algorithm were applied to correct for the partial volume effects of white matter and cerebrospinal fluid on the iVASO difference signal in GM (74). A signal-to-noise ratio (SNR) threshold of one standard deviation below the mean SNR was applied to exclude low SNR voxels from further analysis (73).

The IBASPM116 atlas (75–79) (PickAtlas software, Wake Forest University, NC) was used to identify the preselected anatomical regions based on the literature reviewed in the Introduction, from which average CBVa values were calculated. Group differences in GM CBVa in each region were examined using analysis of covariance with age, sex, education, regional GM volume from anatomical scans, and motion parameters estimated from the motion correction routine in SPM as covariates in the analysis. Effect size was estimated with Cohen’s *d*. All statistical tests were corrected for multiple comparisons by controlling the false discovery rate (adjusted *P* < .05) (80). Note that data from all patients and their corresponding control participants were acquired at the same site and no statistical comparison between the data acquired from different sites was performed in this study.

Note that the current study adopted a region of interest-based analysis strategy to test our hypotheses in preselected brain regions based on literature. CBVa in each brain region identified on magnetic resonance images using the IBASPM116 atlas was averaged and compared. This result is different from that of our previous study on the MCI without movement disorder cohort (13), in which CBVa was compared across the brain on a voxel basis and significant clusters of altered CBVa were identified. CBVa in each cluster within each brain region (which may not cover the entire region) was averaged and compared.

RESULTS

Demographic data for the PD cohorts are summarized in Table 1. Age, sex, and education levels were matched among PD patients with normal or impaired cognition and controls (*P* > .1). Disease duration and UPDRS motor score were matched among PD patients with normal or impaired cognition (*P* = .45). Significant deficits were observed in PD patients with impaired cognition compared with the other 2 groups in the following tests: Logical Memory Subset of the Wechsler Memory Scale (*P* = .02), Controlled Oral Word Association Test (*P* = .007), and HVLT-R (*P* = .02); and trending significant in BNT-60 (*P* = .06).

Demographic data for the MCI without movement disorder cohort are summarized in Table 2. Individuals with MCI and controls in this cohort had matched age, sex, and education levels (*P* > .1). Patients with MCI showed significantly lower scores compared with controls on the Verbal Learning And Memory Test (*P* < .001) and Mini-Mental State Exam (*P* = .01).

The main findings in CBVa changes are summarized in Tables 3–5, and in Figure 1. The CBVa values in controls in all brain regions investigated were in the normal range of CBVa reported for healthy human subjects in the literature (81).

In PD patients with normal cognition (*n* = 10), CBVa was significantly decreased in the substantia nigra (*P* = .04), caudate (*P* = .04), and putamen (*P* = .01) compared with controls (*n* = 7), but comparable with controls in all the other regions investigated.

In PD patients with impaired cognition (*n* = 6), CBVa showed a trend toward decrease in the substantia nigra (*P* = .06), caudate (*P* = .09), and putamen (*P* = .06) compared with controls (*n* = 7). CBVa was significantly increased in the preSMA (*P* = .01) and intracalcarine gyrus (*P* = .03) compared with controls, and it also showed a trend toward increase in the hippocampus (*P* = .07), entorhinal cortex (*P* = .09), and parahippocampus (*P* = .07).

Table 3. Altered Gray Matter CBVa in PD Patients Compared With Controls—CBVa Values in Each Brain Region

Regions	Control (n = 7)		PD Cognitive Normal (n = 10)		PD Cognitive Impaired (n = 6)	
	Mean	SD	Mean	SD	Mean	SD
Substantia Nigra	0.90	0.15	0.63	0.22	0.63	0.31
Caudate	0.90	0.05	0.76	0.26	0.71	0.26
Putamen	0.90	0.09	0.63	0.20	0.63	0.32
Nucleus Accumbens	0.89	0.06	0.85	0.19	0.92	0.07
Posterior Cingulate Cortex	0.93	0.04	0.87	0.20	0.96	0.07
Hippocampus	0.91	0.08	0.90	0.13	1.01	0.12
Entorhinal Cortex	1.00	0.06	1.01	0.05	1.33	0.46
Parahippocampus	0.99	0.10	1.01	0.07	1.35	0.46
Presupplementary Motor Area	1.10	0.08	1.06	0.12	1.34	0.13
Thalamus	0.99	0.09	0.97	0.04	1.09	0.15
Intracalcarine Gyrus	1.08	0.09	1.14	0.45	1.50	0.37
Lingual Gyrus	1.04	0.03	1.04	0.16	1.20	0.24
Nucleus Basalis of Meynert	1.00	0.03	1.02	0.07	1.03	0.09
Cerebellum	1.03	0.01	1.01	0.08	1.04	0.07

In MCI patients without movement disorder (n = 18), CBVa was significantly increased in the caudate (P = .04), putamen (P = .05), hippocampus (P = .02), and lingual gyrus (P = .05) compared with controls (n = 22). CBVa showed a trend toward increase in the nucleus accumbens (P = .08), posterior cingulate

cortex (P = .06), entorhinal cortex (P = .06), and parahippocampus (P = .06).

In all patients with PD and MCI, the CBVa values in the cerebellum were not significantly different from those in controls in the respective cohorts.

Table 4. Altered Gray Matter CBVa in PD Patients Compared With Controls—Statistical Results

Regions	PD Cognitive Normal vs Control					PD Cognitive Impaired vs Control					PD Cognitive Impaired vs PD Cognitive Normal				
	Relative Change (%) ^a	Effect Size ^b	P	t	df ^c	Relative Change (%)	Effect Size	P	t	df	Relative Change (%)	Effect Size	P	t	df
Substantia Nigra	-29.56%	-1.31	.04	-4.32	12	-29.63%	-1.01	.06	-3.04	11	-0.11%	0.01	.99	-0.01	11
Caudate	-14.86%	-0.57	.04	-2.90	15	-20.30%	-0.84	.09	-2.86	10	-6.39%	-0.19	.55	-0.65	12
Putamen	-29.78%	-1.45	.01	-5.96	14	-29.63%	-1.00	.06	-3.29	11	0.21%	0.01	.99	0.02	11
Nucleus Accumbens	-4.04%	-0.21	.38	-0.96	15	3.75%	0.50	.31	1.28	10	8.12%	0.44	.10	1.94	14
Posterior Cingulate Cortex	-6.38%	-0.32	.17	-1.60	15	3.34%	0.48	.27	1.37	11	10.38%	0.54	.06	2.38	14
Hippocampus	-0.99%	-0.08	.80	-0.28	13	11.97%	1.01	.07	2.86	11	13.10%	0.94	.03	3.31	12
Entorhinal Cortex	1.24%	0.23	.65	0.57	11	32.67%	0.88	.09	2.99	10	31.04%	1.14	.10	2.92	10
Parahippocampus	1.96%	0.24	.68	0.53	11	35.36%	0.93	.07	3.10	10	32.75%	1.19	.09	3.06	10
Presupplementary Motor Area	-3.45%	-0.33	.34	-1.18	12	22.37%	2.14	.01	6.21	11	26.75%	2.28	.01	7.73	12
Thalamus	-1.58%	-0.28	.69	-0.51	11	10.48%	0.79	.11	2.27	11	12.25%	1.25	.07	3.35	10
Intracalcarine Gyrus	5.67%	0.15	.48	0.76	15	38.86%	1.36	.03	4.51	10	31.40%	0.85	.03	3.11	13
Lingual Gyrus	0.05%	0.00	.99	0.02	15	15.38%	0.80	.11	2.73	10	15.33%	0.82	.09	2.51	11
Nucleus Basalis of Meynert	1.60%	0.25	.36	-1.33	14	3.33%	0.46	.24	0.81	10	1.71%	0.23	.51	0.97	13
Cerebellum	-1.70%	-0.24	.27	-1.26	14	1.37%	0.26	.47	0.88	10	3.13%	0.41	.19	1.51	13

^a Relative change was defined as 100 × (mean CBVa in patients – mean CBVa in controls)/(mean CBVa in controls) %.

^b Effect size was estimated with Cohen's *d* = (mean CBVa in patients – mean CBVa in controls)/s, where s is the pooled standard deviation of the 2 groups.

^c Degree of freedom.

Table 5. Altered Gray Matter CBVa in Age-Related MCI Patients Without Movement Disorder Compared With Matching Controls

Regions	MCI (n = 18)		Control (n = 22)		Relative Change (%) ^a	Effect Size ^b	P	t	df ^c
	Mean	SD	Mean	SD					
Substantia Nigra	1.15	0.83	1.09	0.88	5.50%	0.07	.59	0.55	31
Caudate	2.31	1.65	1.17	1.31	97.44%	0.77	.04	3.22	35
Putamen	2.15	1.38	1.29	1.01	66.67%	0.72	.05	3.15	35
Nucleus Accumbens	1.52	1.00	1.02	0.99	49.02%	0.50	.08	3.01	32
Posterior Cingulate Cortex	1.55	0.78	1.11	0.82	39.64%	0.55	.06	3.06	32
Hippocampus	1.77	0.93	1.07	0.65	65.42%	0.89	.02	3.33	34
Entorhinal Cortex	1.89	0.78	1.08	0.52	75.00%	1.25	.06	3.05	32
Parahippocampus	1.81	0.53	1.05	0.70	72.38%	1.21	.06	3.05	32
Presupplementary Motor Area	1.76	0.47	1.32	0.52	33.33%	0.88	.12	1.97	36
Thalamus	1.63	0.71	1.17	0.66	39.32%	0.67	.15	1.90	36
Intracalcarine Gyrus	1.82	0.68	1.50	0.77	21.33%	0.44	.13	1.95	36
Lingual Gyrus	1.85	0.88	1.45	0.69	27.59%	0.51	.05	3.12	35
Nucleus Basalis of Meynert	1.21	0.98	1.17	1.00	3.42%	0.04	.60	0.57	35
Cerebellum	1.29	1.01	1.19	0.88	8.40%	0.11	.50	0.69	35

^a Relative change was defined as $100 \times (\text{mean CBVa in patients} - \text{mean CBVa in controls}) / (\text{mean CBVa in controls}) \%$.

^b Effect size was estimated with Cohen's $d = (\text{mean CBVa in patients} - \text{mean CBVa in controls}) / s$, where s is the pooled standard deviation of the 2 groups.

^c Degree of freedom.

DISCUSSION

In this study, microvascular abnormalities as reflected by volume changes in small pial arteries and arterioles (CBVa) were investigated using iVASO MRI in PD patients, MCI patients without movement disorder, and matched controls. As pial arteries and arterioles are the primary regulators of regional perfusion in brain tissues (82–84), CBVa is considered as an indicator of the homeostasis of microvasculature that may provide additional information regarding the underlying neurophysiological changes than behavioral measures and conventional structural MRI. The same MRI scans and analyses were performed in 2 separate cohorts of PD patients and MCI patients without movement disorder and corresponding control groups recruited at 2 sites. This allowed us to better match the controls in each cohort, as the age and many other factors can differ substantially among PD patients and MCI patients without movement disorder. The MRI scans were acquired on a 7T human MRI system with identical hardware and software at both sites. Only data acquired on the same MRI system were compared to minimize the confounding effects from the potential differences between the 2 sites.

Patients with PD who enrolled for this study had an average disease duration of ~3 years and an average UPDRS score of 20–30, which is generally considered to be early stage (but not prodromal) PD (85). The degree of cognitive decline in PD patients with impaired cognition group was mild, as reflected by their performance on the cognitive assessments, and was comparable to that in the MCI patients without movement disorder group as reported in our previous study (13).

The main finding in this study is that PD patients showed significant CBVa *decreases* in the substantia nigra, caudate, and putamen compared with controls, whereas MCI patients without movement disorder and PD patients with impaired cognition showed significant CBVa *increases* in several brain regions closely related to cognition, compared with controls. We interpret the decreased CBVa as an indicator for microvascular damage, especially in the substantia nigra in PD patients, as evidenced in several studies in the literature (15–23). In contrast, similar to our previous studies in MCI patients without movement disorder (13) and Huntington's Disease patients (86) in which the same MRI methods were used, one possible explanation for the elevated CBVa observed in several brain regions may be a *compensatory* mechanism in the earlier stages of the diseases, in which the number of blood vessels increases to normalize the restricted blood flow owing to the reduction of diameter in individual vessels. The exact mechanism is unclear and warrants further investigation that integrates MRI and other imaging and histological techniques.

The substantia nigra is one of the first brain regions that accumulates Lewy bodies in postmortem pathological studies in PD. In our data, CBVa decreased in the substantia nigra in both PD patients with normal cognition and PD patients with impaired cognition. CBVa in the substantia nigra in MCI patients without movement disorder did not show significant changes compared with controls. The dorsal striatum, which consists of the caudate and the putamen, is another region that is known to be affected early in PD. Interestingly, our data showed decreased CBVa in

AQ: G




Figure 1. Comparisons of arteriolar cerebral blood volume (CBVa) values in chosen brain regions between Parkinson's Disease patients with normal cognition, PD patients with impaired cognition (A), and mild cognitive impairment (MCI) patients without movement disorder with matching controls (B). * $P < .05$.

the caudate and putamen in PD patients but increased CBVa in these regions in MCI patients without movement disorder compared with their respective controls.

In this exploratory study, our data seem to suggest that CBVa increase in the preSMA and intracalcarine gyrus, and possibly the hippocampus, entorhinal cortex, and parahippocampus, may be differentiating between PD patients with normal cognition and patients with impaired cognition. The hippocampus, entorhinal cortex, and parahippocampus are closely related to overall cognition and to episodic memory and are known to be affected in dementia (87–91). Our data showed relatively large effect sizes (close to 1) in CBVa increase in these three regions in both PD patients with impaired cognition and MCI patients without movement disorder compared with matching controls. In PD patients with normal cognition, CBVa values in these regions did not show significant changes. The preSMA and intracalcarine gyrus are two regions that are considered to be primarily affected in PDD but not in AD-MCI. In our data, PD patients with impaired cognition showed significantly increased CBVa in these two regions compared with controls, with the largest effect sizes among all regions investigated. No significant changes in CBVa in PD patients with normal cognition and MCI patients without movement disorder were detected in these two regions. In contrast, the opposite CBVa changes in the caudate and putamen, along with CBVa changes in the substantia nigra, nucleus accumbens in the ventral striatum, and the posterior cingulate

cortex, seem to suggest that measuring CBVa in these regions may be key in differentiating between PD patients with impaired cognition and MCI patients without movement disorder. In addition, the lingual gyrus is another region that showed increased CBVa only in the MCI patients without movement disorder cohort. To the best of our knowledge, there are very few studies currently on the potential differential neurovascular changes in different brain regions among PD, PD-MCI, and AD-MCI. The preliminary findings in this study require further investigation and validation in subsequent studies.

The cerebellum is known to be largely spared in the early stages of both PD and AD-MCI. In our data, all PD and MCI patients showed comparable CBVa values in the cerebellum as in controls in respective cohorts. Besides, the CBVa values in all regions in the control subjects were in the normal range of CBVa in human subjects reported in the literature (81). These results provide validation for the CBVa values measured in this study.

No comparison between the MCI patients without movement disorder and PD cohorts were conducted in the analysis described in Results, as the data were acquired on the same type of MRI system but at two different sites. Nevertheless, the CBVa values in the MCI without movement disorder cohort seemed to be slightly greater overall than those in the PD cohort. As CBVa values tend to increase with age (81), one possible explanation is the ~10-year age difference between the patients in MCI and PD cohorts.

There are several limitations in this exploratory study. First, although significant effects were detected in our data, the sample size is small, especially for the PD cohort. Subsequent studies will continue to recruit PD patients with normal and impaired cognition and matched controls at the Johns Hopkins site to validate the current findings. Second, the cross-sectional design is also a fundamental limitation. Future studies with longitudinal measures at different stages of the disease are required to evaluate whether regional CBVa changes can be a predictor for the risk of developing PDD in PD patients. Using the smallest effect size (~ 0.5) for significant between-group CBVa differences detected in this study, we were able to conduct a power analysis that determined we would need ~ 30 participants per group in subsequent studies to achieve a power of 0.8 with $\alpha = 0.05$.

ACKNOWLEDGMENTS

Author Contributions: A.G.P.: Organization and execution of the study, statistical analysis, writing of the manuscript, and review and critique of the manuscript. C.G.: Organization and execution of the study, statistical analysis, writing of the manuscript, and review and critique of the manuscript. S.R.: Organization and execution of the study and review and critique of the manuscript. X.M.: Execution of the study and review and critique of the manuscript. D.C.: Execution of the study and review and critique of the manuscript. V.K.: Execution of the study and review and critique of the manuscript. A.B.: Conception and design, writing of the manuscript, and review and critique of the manuscript. P.G.U.: Conception and design, organization and execution of the study, and review and critique of the manuscript. A.Y.P.: Conception and design, organization and execution of the study, writing of the manuscript, and review and critique of the manuscript. L.S.R.: Conception and design, organization and execution of the study, statistical analysis, writing of the manuscript, and review and critique of the manuscript. J.H.: Conception and design, organization and execution of the study, statistical analysis, writing of the manuscript, and review and critique of the manuscript.

We thank Joseph Gillen, Terri Brawner, Kathleen Kahl, and Ivana Kusevic (F.M. Kirby Research Center) and Grace-Anna Chaney (Psychiatry, Johns Hopkins) for experimental

In summary, CBVa abnormalities in different brain regions were detected in PD patients with normal cognition, in PD patients with impaired cognition, and in MCI patients without movement disorder compared with matched controls by use of iVASO MRI. Our data implies that CBVa changes in several key brain regions may be specific to each condition and thus may provide clues to differentiate one condition from the others. These findings provide further details regarding microvascular abnormalities in different brain regions in PD patients and in MCI patients without movement disorder who have not been reported in existing literature. This may help advance our understanding of the pathophysiology of PDD and may aid the development of imaging biomarkers in PDD. The data from this study will serve as the basis for power analysis for subsequent studies to further investigate and validate the current findings.

assistance; colleagues from the University of Zurich for recruitment of the MCI without movement disorder cohort; and Institute for Biomedical Engineering, ETH Zurich, Switzerland, for 7T MRI scans of the MCI without movement disorder cohort. We also thank Drs. Ted M. Dawson, Zoltan K. Mari, Kelly Mills, Ankur Butala, Emile Moukheiber, and Jee Bang from the Johns Hopkins Parkinson's Disease and Movement Disorder Center for support in the study organization.

Funding sources: This study was supported by the Department of Defense through grant PD160104; the National Institutes of Health through grants R01-NS108452 and P41 EB015909; and KFSP Molecular Imaging Network Zurich, Swiss National Science Foundation, and institutional funding available to the Institute for Biomedical Engineering, University of Zurich, and ETH Zurich, Switzerland.

Statement of Ethics: All experiments were performed according to procedures approved by the Johns Hopkins Institutional Review Boards.

Conflict of Interest: All authors stated that there are no relevant financial disclosure/conflicts.

REFERENCES

- Folynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. *Brain*. 2004;127:550–560.
- Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. *Neurology*. 2017;88:767–774.
- Hobson P, Meara J. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. *Int J Geriatr Psychiatry*. 2015;30:1048–1055.
- Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Wolter R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurol*. 2017;16:55–65.
- Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. *Nat Rev Neurosci*. 2013;14:626–636.
- Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM-Y, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol*. 2012;72:587–598.
- Leeuwis AE, Benedictus MR, Kuijper JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, Koene T, Scheltens P, Barkhoff F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. *Alzheimers Dement*. 2017;13:531–540.
- Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. *Nat Rev Neurosci*. 2017;18:419–434.
- Østergaard L, Aamand R, Gutiérrez-Jiménez E, Ho Y-CL, Blicher JU, Madsen SM, Nagenthiraja K, Dalby RB, Drasbek KR, Møller A, Brændgaard H, Mouridsen K, Jespersen SN, Jensen MS, West MJ. The capillary dysfunction hypothesis of Alzheimer's disease. *Neurobiol Aging*. 2013;34:1018–1031.
- Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. *Acta Neuropathol*. 2009;118:103–113.
- Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. *Nat Rev Neurosci*. 2004;5:347–360.
- Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC. Alzheimer's disease neuroimaging I. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. *Nat Commun*. 2016;7:11934.
- Hua J, Lee S, Blair NIS, Wyss M, van Bergen JMG, Schreiner SJ, Kagerer SM, Leh SE, Giel AF, Treyer V, Buck A, Nitsch RM, Pruessmann KP, Lu H, Van Zijl PCM, Albert M, Hock C, Unsöld PG. Increased cerebral blood volume in small arterial vessels is a correlate of amyloid-beta-related cognitive decline. *Neurobiol Aging*. 2019;76:181–193.
- Chahine LM, Dos Santos C, Fullard M, Scordia C, Weintraub D, Erus G, Rosenthal L, Davatzikos C, McMillan CT. Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. *Eur J Neurol*. 2019;26:246–e18.
- Jagut WJ, Reed BR, Martin EM, Eberling JL, Nelson-Abbott RA. Cognitive function and regional cerebral blood flow in Parkinson's disease. *Brain*. 1992;115:521–537.
- Markus HS, Costa DC, Lees AJ. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. *J Neurol Neurosurg Psychiatry*. 1994;57:180–185.
- Tachibana H, Tomino Y, Kawabata K, Sugita M, Fukuchi M. Twelve-month follow-up study of regional cerebral blood flow in Parkinson's disease. *Dementia*. 1995;6:89–93.
- Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. *Neurol Sci*. 2001;22:45–46.

19. Abe Y, Kachi T, Kato T, Arahata Y, Yamada T, Washimi Y. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. *J Neurol Neurosurg Psychiatry*. 2003;74:419–422.
20. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. *Neuroimage*. 2003;20:1309–1319.
21. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. *Lancet*. 1999;353:981–982.
22. Wada K, Arai H, Takanashi M, Fukae J, Oizumi H, Yasuda T, Mizuno Y, Mochizuki H. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. *Neuroreport*. 2006;17:705–709.
23. Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londo E, Cenci MA, Hansson O. Increased CSF biomarkers of angiogenesis in Parkinson disease. *Neurology*. 2015;85:1834–1842.
24. Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kim JW. Dementia with Lewy bodies versus Alzheimer's disease and Parkinson's disease dementia: a comparison of cognitive profiles. *J Clin Neurol*. 2011;7:19–24.
25. Freedman M, Oscar-Berman M. Comparative neuropsychology of cortical and subcortical dementia. *Can J Neurol Sci*. 1986;13:410–414.
26. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. *Neurology*. 2009;72:1048–1055.
27. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging*. 1995;16:271–278. discussion 8–84.
28. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. *Neurobiol Aging*. 2001;22:747–754.
29. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*. 2003;24:197–211.
30. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology*. 2017;89:88–100.
31. Ravizza SM, Goudreau J, Delgado MR, Ruiz S. Executive function in Parkinson's disease: contributions of the dorsal frontostriatal pathways to action and motivation. *Cogn Affect Behav Neurosci*. 2012;12:193–206.
32. MacDonald V, Halliday GM. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. *Mov Disord*. 2002;17:1166–1173.
33. Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WR. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. *Mov Disord*. 2007;22:382–386.
34. Aron AR, Behrens TE, Smith S, Frank MJ, Poldrack RA. Triangulating a cognitive control network using diffusion-weighted magnetic resonance imaging (MRI) and functional MRI. *J Neurosci*. 2007;27:3743–3752.
35. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann Neurol*. 1997;42:85–94.
36. Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ, Barker RA. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. *Brain*. 2014;137:2743–2758.
37. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ. Grey matter atrophy in cognitively impaired Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2012;83:188–194.
38. Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, Udaka F. Heterogeneous factors in dementia with Parkinson's disease: IMP-SPECT study. *Parkinsonism Relat Disord*. 2007;13:174–181.
39. Peraza LR, Colloby SJ, Firbank MJ, Greasy GS, McKeith IG, Kaiser M, O'Brien J, Taylor JP. Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences. *Int J Geriatr Psychiatry*. 2015;30:1135–1146.
40. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. *J Neurosci*. 2003;23:6351–6356.
41. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitich D, deToledo-Morrell L, Goetz CG. Visuo-perceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. *Brain*. 2014;137:849–859.
42. Möller C, Dieleman N, van der Flier WM, Versteeg A, Pijnenburg Y, Scheltens P, Barkhof F, Vrenken H. More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. *J Alzheimers Dis*. 2015;44:635–647.
43. Nie X, Sun Y, Wan S, Zhao H, Liu R, Li X, Wu S, Nedelska Z, Hort J, Qing Z, Xu Y, Zhang B. Subregional Structural Alterations in Hippocampus and Nucleus Accumbens Correlate with the Clinical Impairment in Patients with Alzheimer's Disease Clinical Spectrum: parallel Combining Volume and Vertex-Based Approach. *Front Neurol*. 2017;8:399.
44. Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease. *Acta Neuropathol*. 2015;129:527–540.
45. Hua J, Qin Q, Donahue MJ, Zhou J, Pekar JJ, van Zijl PC. Inflow-based vascular-space-occupancy (iVASO) MRI. *Magn Reson Med*. 2011;66:40–56.
46. Hua J, Qin Q, Pekar JJ, Zijl PC. Measurement of absolute arterial cerebral blood volume in human brain without using a contrast agent. *NMR Biomed*. 2011;24:1313–1325.
47. Hua J, Qin Q, Donahue MJ, Zhou J, Pekar J, van Zijl PC, editors. Functional MRI Using Arteriolar Cerebral Blood Volume Changes. Proc 17th Annual Meeting ISMRM; 2009; HI, USA.
48. Hua J, Qin Q, Pekar J, van Zijl PC, editors. Measuring Absolute Arteriolar Cerebral Blood Volume (CBVa) in Human Brain Gray Matter (GM) without Contrast Agent. Proc 17th Annual Meeting ISMRM; 2009; HI, USA.
49. Donahue MJ, MacIntosh BJ, Sideso E, Bright M, Kennedy J, Handa A, Jezzard P, editors. Absolute cerebral blood volume (CBV) quantification without contrast agents using inflow vascular-space-occupancy (iVASO) with dynamic subtraction. Proc 17th Annual Meeting ISMRM; 2009; HI, USA.
50. Donahue MJ, Sideso E, MacIntosh BJ, Kennedy J, Handa A, Jezzard P. Absolute arterial cerebral blood volume quantification using inflow vascular-space-occupancy with dynamic subtraction magnetic resonance imaging. *J Cereb Blood Flow Metab*. 2010;30:1329–1342.
51. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. *Nat Neurosci*. 2007;10:1369–1376.
52. Ito H, Ibaraki M, Kanno I, Fukuda H, Miura S. Changes in the arterial fraction of human cerebral blood volume during hypercapnia and hypocapnia measured by positron emission tomography. *J Cereb Blood Flow Metab*. 2005;25:852–857.
53. Ito H, Kanno I, Iida H, Hatazawa J, Shimosegawa E, Tamura H, Okudera T. Arterial fraction of cerebral blood volume in humans measured by positron emission tomography. *Ann Nucl Med*. 2001;15:111–116.
54. Kim T, Hendrich KS, Masamoto K, Kim SG. Arterial versus total blood volume changes during neural activity-induced cerebral blood flow change: implication for BOLD fMRI. *J Cereb Blood Flow Metab*. 2007;27:1235–1247.
55. Takano T, Tian G-F, Peng W, Lou N, Libionka W, Han X, Nedergaard M. Astrocyte-mediated control of cerebral blood flow. *Nat Neurosci*. 2006;9:260–267.
56. Balbi M, Ghosh M, Longden TA, Vega MJ, Gesierich B, Hellal F, Lourbopoulos A, Nelson MT, Plesnila N. Dysfunction of mouse cerebral arteries during early aging. *J Cereb Blood Flow Metab*. 2015;35:1445–1453.
57. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015;30:1591–1601.
58. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinical profile. *Mov Disord*. 2008;23:2398–2403.
59. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinical testing results. *Mov Disord*. 2008;23:2129–2170.
60. World Medical Association. Declaration of Helsinki. *Law Med Health Care*. 1991;19:264–265.
61. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7:270–279.
62. Hunsley J, Lee CM. Introduction to clinical psychology: An evidence-based approach. NY, NY: John Wiley & Sons, Inc.; 2010.
63. Gregoire J, Van der Linden M. Effect of age on forward and backward digit spans. *Aging, Neuropsychology, and Cognition*. 1997;4:140–149.
64. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines. *Mov Disord*. 2012;27:349–356.

65. Nicholas LE, Brookshire RH, MacLennan DL, Schumacher JG, Porrazzo SA. The Boston Naming Test: revised administration and scoring procedures and normative information for non-brain-damaged adults. *Clinical Aphasiology*. 1989;3:103–115.
66. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. *Arch Clin Neuropsychol*. 2004;19:203–214.
67. Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG, Thal LJ. Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. *J Int Neuropsychol Soc*. 2002;8:943–955.
68. Marques JP, Kober T, Krueger G, van der Zwaag W, Van de Moortele PF, Gruetter R. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. *Neuroimage*. 2010;49:1271–1281.
69. Van de Moortele P-F, Auerbach EJ, Olman C, Yacoub E, Uğurbil K, Moeller S. T1 weighted brain images at 7 Tesla unbiased for Proton Density, T2* contrast and RF coil receive B1 sensitivity with simultaneous vessel visualization. *Neuroimage*. 2009;46:432–446.
70. Hua J, Jones CK, Qin Q, van Zijl PC. Implementation of vascular-space-occupancy MRI at 7T. *Magn Reson Med*. 2013;69:1003–1013.
71. Hua J, Brandt AS, Lee S, Blair NIS, Wu Y, Lui S, Patel J, Faria AV, Lim IAL, Unschuld PG, Pekar JJ, van Zijl PCM, Ross CA, Margolis RL. Abnormal grey matter arteriolar cerebral blood volume in schizophrenia measured with 3D inflow-based vascular-space-occupancy MRI at 7T. *Schizophr Bull*. 2017;43:620–632.
72. Lu H, Donahue MJ, van Zijl PC. Detrimental effects of BOLD signal in arterial spin labeling fMRI at high field strength. *Magn Reson Med*. 2006;56:546–552.
73. Hua J, Qin Q, Pekar JJ, Zijl PC. Measurement of absolute arterial cerebral blood volume in human brain without using a contrast agent. *NMR Biomed*. 2011;24:1313–1325.
74. Johnson NA, Jahng G-H, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. *Radiology*. 2005;234:851–859.
75. Lancaster JL, Rainey LH, Summerlin JL, Freitas CS, Fox PT, Evans AC, Toga AW, Mazziotta JC. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method. *Hum Brain Mapp*. 1997;5:238–242.
76. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, Kochunov PV, Nickerson D, Mikiten SA, Fox PT. Automated Talairach atlas labels for functional brain mapping. *Hum Brain Mapp*. 2000;10:120–131.
77. Maldjian JA, Laurienti PJ, Burdette JH. Precentral gyrus discrepancy in electronic versions of the Talairach atlas. *Neuroimage*. 2004;21:450–455.
78. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. *Neuroimage*. 2003;19:1233–1239.
79. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002;15:273–289.
80. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B*. 1995;57:289–300.
81. Hua J, Liu P, Kim T, Donahue M, Rane S, Chen JJ, Qin Q, Kim S-G. MRI techniques to measure arterial and venous cerebral blood volume. *Neuroimage*. 2019;187
82. Mchedlishvili G. *Arterial Behavior and Blood Circulation in the Brain*. NY: Plenum Press; 1986.
83. Auer LM, Johansson BB. Dilatation of pial arterial vessels in hypercapnia and in acute hypertension. *Acta Physiol Scand*. 1980;109:249–251.
84. Mchedlishvili GI, Baramidze DG, Nicolaishvili LS, Mamisashvili VA. Vascular mechanisms responsible for microcirculation of the cerebral cortex. *Biochem Exp Biol*. 1974;11:113–129.
85. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. MDS research criteria for prodromal Parkinson's disease. *Mov Disord*. 2015;30:1600–1611.
86. Hua J, Unschuld PG, Margolis RL, van Zijl PC, Ross CA. Elevated arteriolar cerebral blood volume in prodromal Huntington's disease. *Mov Disord*. 2014;29:396–401.
87. Bakker A, Albert MS, Krauss G, Speck CL, Gallagher M. Response of the medial temporal lobe network in amnesic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. *Neuroimage Clin*. 2015;7:688–698.
88. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnesic mild cognitive impairment. *Neuron*. 2012;74:467–474.
89. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. *Neurology*. 2005;65:404–411.
90. Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnesic Mild Cognitive Impairment. *Neuroimage*. 2010;51:1242–1252.
91. Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, Mayeux R, Duff KE, Small SA. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. *Nat Neurosci*. 2014;17:304–311.